Why choose Biocytogen's BsADC assets?

Targeting two tumor-associated antigens with a bispecific ADC (bsADC) is a therapeutic strategy to reduce off-tumor toxicity and improve antitumor efficacy. To enable discovery of novel bsADCs for this purpose, our team developed a large-scale bsADC platform with these key advantages:

• Fully Human, Common Light Chain Antibodies: Our RenLite mice produce genetically diverse, fully human common light chain antibody backbones, which can be assembled into Y-shaped bispecific antibodies to facilitate the CMC process.
• Novel Linker/Payload: Use of a proprietary linker/payload system, BLD1102, which is composed of a super hydrophilic and cleavable linker, and a novel topoisomerase I inhibitor payload BCPT02 with high potency and strong bystander killing effect. It also demonstrated a favorable safety profile in cynomolgus monkey.

Our BsADC projects

Our TAA antibody library

Selected assets overview

Biocytogen has reached some agreements with ADC companies around the world, including IDEAYA, ABL Bio, Ona Therapeutics and ADC Therapeutics. Contact us today to explore evaluation, licensing, or co-development opportunities!

SEZ6×B7H3 bsADC

Highlights of our assets:

• Demonstrates high affinity for both human and monkey antigens
• Exhibits enhanced internalization in SCLC cell line
• Shows exceptional anti-tumor efficacy in xenograft models
• Outperforms individual SEZ6 or B7H3 ADCs
• Effective in both SCLC cell line-derived xenografts (CDX) and B7H3-expressing patient-derived xenografts (PDX)
• Ongoing studies are evaluating the use of a topoisomerase I inhibitor (TOPO1i) payload for enhanced therapeutic outcomes

The SEZ6 × B7H3-vcMMAE showed a synergistic effect, surpassing the performance of benchmark ADCs in an SCLC model

PTK7 x TROP2 BsADC (BCG033)

Highlights of our assets:

• The clinical efficacy of TRODELVY is limited by the toxicity of this single-target agent. To improve the therapeutic window and increase the efficacy, we sought to develop a TROP2-related bsADC for metastatic TNBC.
• PTK7 is highly expressed in breast cancer, especially in TNBC. PTK7 also is enriched in tumor-initiating cells.
• BCG033 is a novel anti-PTK7 x TROP2 bsADC, which exhibited superior anti-tumor efficacy to the benchmark ADCs in vivo.

Co-expression of PTK7 x TROP2 in multiple cancer cell types

Superior anti-tumor efficacy to benchmark ADCs in xenograft models